Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
D. K. Walker, J. Davis, C. Houle, I. B. Gardner & R. Webster. (2009) Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations. Xenobiotica 39:7, pages 534-543.
Read now
Read now
Rakesh Dixit, Jim Riviere, Kannan Krishnan & Melvin Andersen. (2003) Toxicokinetics and Physiologically Based Toxicokinetics in Toxicology and Risk Assessment. Journal of Toxicology and Environmental Health, Part B 6:1, pages 1-40.
Read now
Read now
D. K. Walker, K. C. Beaumont, P. Comby, K. M. Evans, J. I. Gedge, R. C. Halliday, S. J. Roffey & P. A. Wright. (2001) Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. Xenobiotica 31:8-9, pages 651-664.
Read now
Read now
D. K. WALKER. (1999) Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 29:3, pages 297-310.
Read now
Read now
D. A. SMITH. (1997) Pharmacokinetics and pharmacodynamics in toxicology. Xenobiotica 27:5, pages 513-525.
Read now
Read now
M. J. Humphrey. (1996) Application of Metabolism and Pharmacokinetic Studies to the Drug Discovery Process. Drug Metabolism Reviews 28:3, pages 473-489.
Read now
Read now
Y. Tanaka, H. Shimojyo, T. Hata, M. Hashimoto & H. Noguchi. (1994) Toxicokinetics of zenarestat, an aldose reductase inhibitor in animals and man. Xenobiotica 24:5, pages 461-471.
Read now
Read now
M. J. Humphrey & D. A. Smith. (1992) Role of metabolism and pharmacokinetic studies in the discovery of new drugs—present and future perspectives. Xenobiotica 22:7, pages 743-755.
Read now
Read now
D. A. Smith, H. S. Rasmussen, D. A. Stopher & D. K. Walker. (1992) Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 22:6, pages 709-719.
Read now
Read now
D. A. Smith, K. Beaumont, N. J. Cussans, M. J. Humphrey, S. G. Jezequel, D. J. Rance, D. A. Stopher & D. K. Walker. (1992) Bioanalytical data in decision making: Discovery and development. Xenobiotica 22:9-10, pages 1195-1205.
Read now
Read now
Articles from other publishers (26)
Ferhat Özen & Gökhan Eraslan. (2022) Toxicokinetic of cyphenothrin in rabbits. Environmental Science and Pollution Research 29:21, pages 31541-31550.
Crossref
Crossref
Eun-Jeong Choi, Go-Wun Choi, Seung-Jeong Yang, Yong-Bok Lee & Hea-Young Cho. (2018) Pharmacokinetic Profile of Kaurenoic Acid after Oral Administration of Araliae Continentalis Radix Extract Powder to Humans. Pharmaceutics 10:4, pages 253.
Crossref
Crossref
Jianghong Fan & Inés A.M. de Lannoy. (2014) Pharmacokinetics. Biochemical Pharmacology 87:1, pages 93-120.
Crossref
Crossref
Jos G.M. Bessems & Liesbeth Geraets. (2013) Proper knowledge on toxicokinetics improves human hazard testing and subsequent health risk characterisation. A case study approach. Regulatory Toxicology and Pharmacology 67:3, pages 325-334.
Crossref
Crossref
Alexander V. LyubimovRoger N. Hayes. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
29
.
Claude Charuel. 2011. Pharmaceutical Toxicology in Practice. Pharmaceutical Toxicology in Practice
83
107
.
Clarence N. Ahlem, Theodore M. Page, Dominick L. Auci, Michael R. Kennedy, Katia Mangano, Ferdinando Nicoletti, Yu Ge, Yujin Huang, Steven K. White, Sonia Villegas, Douglas Conrad, Angela Wang, Christopher L. Reading & James M. Frincke. (2011) Novel components of the human metabolome: The identification, characterization and anti-inflammatory activity of two 5-androstene tetrols. Steroids 76:1-2, pages 145-155.
Crossref
Crossref
Peter L. BonatePeter L. Bonate. 2011. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. Pharmacokinetic-Pharmacodynamic Modeling and Simulation
303
358
.
Hong Mei & Richard Morrison. 2009. Using Mass Spectrometry for Drug Metabolism Studies, Second Edition. Using Mass Spectrometry for Drug Metabolism Studies, Second Edition
59
98
.
J English. 2006. Toxicological Testing Handbook. Toxicological Testing Handbook
79
107
.
Rakesh Dixit. 2006. Biological Concepts and Techniques in Toxicology. Biological Concepts and Techniques in Toxicology
117
160
.
D. K. Walker. (2004) The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. British Journal of Clinical Pharmacology 58:6, pages 601-608.
Crossref
Crossref
. 2002. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists
175
188
.
D A Beatty & W W Piegorsch. (2016) Optimal statistical design for toxicokinetic studies. Statistical Methods in Medical Research 6:4, pages 359-376.
Crossref
Crossref
Harry Mager & Gernot Göller. (1997) Comments on the Statistical Analysis of Toxicokinetic Studies. Drug Information Journal 31:2, pages 551-562.
Crossref
Crossref
Mitchell N. Cayen. (2016) Considerations in the Design of Toxicokinetic Programs. Toxicologic Pathology 23:2, pages 148-157.
Crossref
Crossref
Peter G. Welling. (2016) Differences Between Pharmacokinetics and Toxicokinetics. Toxicologic Pathology 23:2, pages 143-147.
Crossref
Crossref
Dennis A. Smith. (1994) Design of drugs through a consideration of drug metabolism and pharmacokinetics. European Journal of Drug Metabolism and Pharmacokinetics 19:3, pages 193-199.
Crossref
Crossref
Alastair Monro. (1994) Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses. Journal of Pharmacokinetics and Biopharmaceutics 22:1, pages 41-57.
Crossref
Crossref
Per Sjöberg. (2016) Toxicokinetics in Preclinical Safety Assessment—Views of the Swedish Medical Products Agency. Drug Information Journal 28:1, pages 151-157.
Crossref
Crossref
David Case. (2016) Toxicokinetics: Some Definitions. Drug Information Journal 28:1, pages 145-149.
Crossref
Crossref
C. Charuel. 1994. Use of Mechanistic Information in Risk Assessment. Use of Mechanistic Information in Risk Assessment
242
249
.
Tomoo Funaki, Hideko Onodera, Kotaro Ogawa, Shigeyasu Ichihara, Hideo Fukazawa & Isami Kuruma. (1993) Simultaneous determination of a new anticancer drug galocitabine and its metabolites in blood by high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis 11:4-5, pages 379-384.
Crossref
Crossref
D. A. Smith. (1993) Integration of animal pharmacokinetic and pharmacodynamic data in drug safety assessment. European Journal of Drug Metabolism and Pharmacokinetics 18:1, pages 31-39.
Crossref
Crossref
Heinz Nau. 1993. Use of Biomarkers in Assessing Health and Environmental Impacts of Chemical Pollutants. Use of Biomarkers in Assessing Health and Environmental Impacts of Chemical Pollutants
121
136
.
N.W. Spurling & P.F. Carey. (2016) Dose Selection for Toxicity Studies: A Protocol for Determining the Maximum Repeatable Dose. Human & Experimental Toxicology 11:6, pages 449-457.
Crossref
Crossref